Jinarc recommended for approval in rare kidney disease

View source ↗

Summary

EMA recommends approval of Jinarc for a rare kidney disease, indicating a potential new treatment option pending final EU authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sorry Cannot Determine the Exact Disease From the Provided Information

Drugs mentioned

• JINARC (tolvaptan)